Becoming a physician and researcher has fulfilled my desire to help others. Early in my residency, I was drawn to pediatric hematology-oncology and later, during my fellowship, I became interested in bone marrow transplantation. I continue to enjoy working with children because it’s very rewarding to see a sick child turn the corner and do well.
In patient care, I specialize in bone marrow transplantation for hemoglobinopathies, malignancies and metabolic disorders. I also run a multidisciplinary clinic focused on taking care of children with chronic graft versus host disease. With my research, I work to restore and maintain intestinal homeostasis in patients during the peri-transplant period.
My goal is to reduce the incidence of graft versus host disease (GVHD) by using a variety of approaches, such as administration of specific nutritional compounds and modification of the intestinal microbiome. Since GVHD can be a life-threatening complication after bone marrow transplants, I am interested in improving outcomes for patients by reducing its occurrence.
MD: Kasturba Medical College, Manipal, India, 2005.
Residency: University of Arizona College of Medicine, Tucson, AZ, 2010.
Fellowship: Cincinnati Children's Hospital Medical Center, 2013.
Pediatric bone marrow transplantation; acute graft versus host disease
Cancer and Blood Diseases, Bone Marrow Transplantation BMT, Rare Lung Diseases
Acute graft versus host disease biology; treatment of steroid refractory acute graft versus host disease; management of refractory autoimmune cytopenias in the post-transplant setting
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
CCR5 inhibitor as novel acute graft versus host disease prophylaxis in children and young adults undergoing allogeneic stem cell transplant: results of the phase II study. Bone Marrow Transplantation. 2020; 55:1552-1559.
Ibrutinib for the treatment of chronic graft-vs-host disease in pediatric hematopoietic stem cell transplant patients: A single-center experience. Pediatric Transplantation. 2020; 24:e13692.
CD38brightCD8+ T Cells Associated with the Development of Acute GVHD Are Activated, Proliferating, and Cytotoxic Trafficking Cells. Biology of Blood and Marrow Transplantation. 2020; 26:1-6.
A Pilot Study of Human Milk to Reduce Intestinal Inflammation After Bone Marrow Transplant. Breastfeeding Medicine. 2019; 14:193-202.
Hematopoietic Stem Cell Transplantation Activity in Pediatric Cancer between 2008 and 2014 in the United States: A Center for International Blood and Marrow Transplant Research Report. Biology of Blood and Marrow Transplantation. 2017; 23:1342-1349.
Ruxolitinib as Salvage Therapy in Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Hematopoietic Stem Cell Transplant Patients. Biology of Blood and Marrow Transplantation. 2017; 23:1122-1127.
A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 2016; 22:2220-2225.
A Single-Center Experience Comparing Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning with Myeloablative Busulfan, Cyclophosphamide, and Antithymocyte Globulin for Chronic Granulomatous Disease. Biology of Blood and Marrow Transplantation. 2016; 22:2011-2018.
A Pharmacokinetic and Pharmacodynamic Study of Maraviroc as Acute Graft-versus-Host Disease Prophylaxis in Pediatric Allogeneic Stem Cell Transplant Recipients with Nonmalignant Diagnoses. Biology of Blood and Marrow Transplantation. 2016; 22:1829-1835.
Bortezomib for refractory autoimmunity in pediatrics. Biology of Blood and Marrow Transplantation. 2014; 20:1654-1659.